Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Health authorities in Rio de Janeiro are reviewing samples from 288 donors after discovering that two HIV-positive people ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...